Member Exclusive 2021 Webinar: Patient Advocacy and Access to Innovative Clinical Trials in a Changed Environment (COVID 19)
-
Register
- Member - Free!
- Advanced Practice Professional Member - Free!
- Complimentary Member - Free!
- Industry Community - Free!
- Industry Community Sub Account - Free!
- Laboratory Member - Free!
- Laboratory Technologist Sub Account - Free!
- Laboratory Regular Member Sub Account - Free!
- Laboratory Resident and Fellow Sub Account - Free!
- Regular Member - Free!
- Resident or Fellow Member - Free!
- Student Member - Free!
- Technologist Member - Free!
Already registered?
Log in now.
Presented by the ISCT Market Access & Patient Advocacy (MAPA) Commercialization Subcommittee
April 7, 2021
Webinar Description:
- What is the ethical protocol of approaching patients for early-stage clinical trials i.e. determining what is the reasonable ratio between risks and benefits, and the role of the FDA and EMA?
- What are the key differences between CGT clinical trials compared to the traditional model?
- How has COVID-19 changed accessibility, resource planning and management of CGT trials and what are the best practices for working lean?
- What is the clinical perspective of the most forceful challenges posed by COVID-19 when conducting Clinical Trials?
- How has patient advocacy and support changed in the face of COVID-19?
Dr. Gerhard Bauer (Moderator)
Director of GMP Facility
Institute For Regenerative Cures (IRC)
Mark Yarborough, PhD
Deans Professor of Bioethics
Center for Neuroengineering & Medicine, University of California Davis
Tamie Joeckel
Global Business Lead
Cell and Gene Therapy Center of Excellence at ICON
Steven Devine, MD, PhD
Chief Medical Officer
National Marrow Donor Program (NMDP)
Complete
Next
Failed
Available
Locked